Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.578

-3.6%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	11/11/2008 10:37:10 AM
	Read Replies (1) of 368

Piper Jaffray Co. Downgrades Sangamo BioSciences (SGMO) to Sell Piper Jaffray Co. downgrades Sangamo BioSciences (Nasdaq: SGMO) from Hold to Sell. Price target lowered from $12 to $1. Piper analyst says, "At this point, we are skeptical of the future of SB-509 in DN given that the drug failed in a larger trial in less severe patients. We also believe this failure raises larger questions about the therapeutic potential of ZFPs and greatly reduces the chances for a FP partnership in the near-term...Sangamo is also conducting a trial in mild-to-moderate DN patients to assess the roll of stem cell mobilization in these patients and in September began Study #809 in Amyotrophic Lateral Sclerosis (ALS). We have low expectations for the stem cell mobilization study adding value in DN and are skeptical that SB-509 will show efficacy in ALS, which has proven extremely difficult to treat. We also have low expectations for the rest of Sangamo's preclinical, ex-vivo pipeline looking at treatments for AIDS and gliobastoma." Sangamo BioSciences, Inc. (Sangamo) is engaged in the development and commercialization of transcription factors for gene regulation and gene modification.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next